{"slideshow_credits": null, "snippet": "Sidney Gilman, a top Alzheimer\u2019s researcher, oversaw the trials for a drug developed by Wyeth and Elan that had the potential to help Alzheimer\u2019s patients. Just days before publicly presenting disappointing results from the drug\u2019s trial in...", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "multimedia", "byline": null, "web_url": "http://www.nytimes.com/interactive/2012/12/15/business/Elan-stocks-rise-and-fall.html", "lead_paragraph": "Sidney Gilman, a top Alzheimer\u2019s researcher, oversaw the trials for a drug developed by Wyeth and Elan that had the potential to help Alzheimer\u2019s patients. Just days before publicly presenting disappointing results from the drug\u2019s trial in 2008, Dr. Gilman provided the data to Mathew Martoma, a trader affiliated with SAC Capital, prosecutors say, allowing Mr. Martoma to sell the stock and avoid big losses.", "headline": {"seo": "Elan Stock\u2019s Rise and Fall", "main": "A Stock\u2019s Rise and Fall"}, "_id": "50ccf70000315214fbb7f95f", "word_count": 76, "multimedia": [], "pub_date": "2012-12-15T00:00:00Z", "source": "The New York Times", "news_desk": "Business Day", "keywords": [{"name": "organizations", "value": "SAC Capital Advisors", "rank": "3"}, {"name": "subject", "value": "Insider Trading", "rank": "2"}, {"name": "subject", "value": "Dementia", "rank": "1"}], "blog": [], "subsection_name": null, "type_of_material": "Interactive Feature"}